Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review
|
Jan 2024
|
Journal of Women's Health
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
|
Jan 2024
|
Lancet Hematology
|
myelodysplastic syndromes (MDS)
|
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
|
Jan 2024
|
Lancet
|
myelodysplastic syndromes (MDS)
|
T cell dysfunctions in myelodysplastic syndromes
|
Jan 2024
|
Blood
|
myelodysplastic syndromes (MDS)
|
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
|
Jan 2024
|
Lancet Hematology
|
myelodysplastic syndromes (MDS)
|
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
|
Jan 2024
|
Lancet Hematology
|
myelodysplastic syndromes (MDS)
|
Paroxysmal Nocturnal Hemoglobinuria
|
Jan 2024
|
StatPearls
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy
|
Jan 2024
|
Mediterranean Journal of Hematology and Infectious Diseases
|
myelodysplastic syndromes (MDS)
|
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study
|
Dec 2023
|
Leukemia
|
aplastic anemia
|
Morphologic Characteristics of Myelodysplastic Syndromes
|
Dec 2023
|
Clinics in Laboratory Medicine
|
myelodysplastic syndromes (MDS)
|